Louis Renzetti has been appointed chief scientific officer of New York-based Bridge Medicines. Renzetti most recently worked as chief research and early development officer of Gotham Therapeutics, another New York biotech startup. Before that, he was senior vice president of drug discovery and early development for Waltham, MA-based X-Rx. His experience also includes early drug discovery work at Roche. Bridge launched in 2016, aiming to develop drug candidates that come from academic institutions.